Free Trial
Your $100 Credit Is Waiting! Get MarketBeat All Access Today
Lock In $149
Claim MarketBeat All Access Sale Promotion

Sernova (SVA) Competitors

Sernova logo
C$0.15 -0.01 (-3.23%)
As of 02:16 PM Eastern

SVA vs. TH, BCT, IPA, HBP, and SCYB

Should you buy Sernova stock or one of its competitors? MarketBeat compares Sernova with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sernova include Theratechnologies (TH), BriaCell Therapeutics (BCT), ImmunoPrecise Antibodies (IPA), Helix BioPharma (HBP), and Scythian Biosciences (SCYB). These companies are all part of the "biotechnology" industry.

How does Sernova compare to Theratechnologies?

Theratechnologies (TSE:TH) and Sernova (TSE:SVA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, dividends, earnings, institutional ownership and analyst recommendations.

Theratechnologies has a beta of 0.256166, indicating that its stock price is 74% less volatile than the broader market. Comparatively, Sernova has a beta of -0.276836, indicating that its stock price is 128% less volatile than the broader market.

Sernova has a net margin of 0.00% compared to Theratechnologies' net margin of -19.83%. Sernova's return on equity of 51.72% beat Theratechnologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Theratechnologies-19.83% 47.31% 5.15%
Sernova N/A 51.72%-119.26%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Theratechnologies
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Sernova
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Theratechnologies has higher revenue and earnings than Sernova. Theratechnologies is trading at a lower price-to-earnings ratio than Sernova, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TheratechnologiesC$84.38M2.44-C$1.96M-C$0.19N/A
SernovaN/AN/A-C$35.70M-C$0.04N/A

0.5% of Theratechnologies shares are owned by institutional investors. Comparatively, 0.0% of Sernova shares are owned by institutional investors. 1.2% of Theratechnologies shares are owned by company insiders. Comparatively, 12.1% of Sernova shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Theratechnologies' average media sentiment score of 0.00 equaled Sernova'saverage media sentiment score.

Company Overall Sentiment
Theratechnologies Neutral
Sernova Neutral

Summary

Theratechnologies beats Sernova on 6 of the 11 factors compared between the two stocks.

How does Sernova compare to BriaCell Therapeutics?

BriaCell Therapeutics (CVE:BCT) and Sernova (TSE:SVA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk.

In the previous week, BriaCell Therapeutics had 1 more articles in the media than Sernova. MarketBeat recorded 1 mentions for BriaCell Therapeutics and 0 mentions for Sernova. BriaCell Therapeutics' average media sentiment score of 0.00 equaled Sernova'saverage media sentiment score.

Company Overall Sentiment
BriaCell Therapeutics Neutral
Sernova Neutral

BriaCell Therapeutics is trading at a lower price-to-earnings ratio than Sernova, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BriaCell TherapeuticsN/AN/AN/A-C$0.38N/A
SernovaN/AN/A-C$35.70M-C$0.04N/A

0.0% of Sernova shares are owned by institutional investors. 12.1% of Sernova shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Sernova's return on equity of 51.72% beat BriaCell Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
BriaCell TherapeuticsN/A N/A N/A
Sernova N/A 51.72%-119.26%

Summary

Sernova beats BriaCell Therapeutics on 5 of the 7 factors compared between the two stocks.

How does Sernova compare to ImmunoPrecise Antibodies?

Sernova (TSE:SVA) and ImmunoPrecise Antibodies (CVE:IPA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations.

0.0% of Sernova shares are owned by institutional investors. 12.1% of Sernova shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Sernova's return on equity of 51.72% beat ImmunoPrecise Antibodies' return on equity.

Company Net Margins Return on Equity Return on Assets
SernovaN/A 51.72% -119.26%
ImmunoPrecise Antibodies N/A N/A N/A

In the previous week, Sernova's average media sentiment score of 0.00 equaled ImmunoPrecise Antibodies'average media sentiment score.

Company Overall Sentiment
Sernova Neutral
ImmunoPrecise Antibodies Neutral

ImmunoPrecise Antibodies has higher revenue and earnings than Sernova. ImmunoPrecise Antibodies is trading at a lower price-to-earnings ratio than Sernova, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SernovaN/AN/A-C$35.70M-C$0.04N/A
ImmunoPrecise AntibodiesC$19.47M8.33-C$22.19M-C$0.89N/A

Summary

Sernova beats ImmunoPrecise Antibodies on 5 of the 8 factors compared between the two stocks.

How does Sernova compare to Helix BioPharma?

Sernova (TSE:SVA) and Helix BioPharma (TSE:HBP) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

0.0% of Sernova shares are held by institutional investors. Comparatively, 0.0% of Helix BioPharma shares are held by institutional investors. 12.1% of Sernova shares are held by company insiders. Comparatively, 2.2% of Helix BioPharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Sernova's return on equity of 51.72% beat Helix BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
SernovaN/A 51.72% -119.26%
Helix BioPharma N/A -36.79%-279.98%

Helix BioPharma is trading at a lower price-to-earnings ratio than Sernova, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SernovaN/AN/A-C$35.70M-C$0.04N/A
Helix BioPharmaN/AN/A-C$50.55M-C$0.06N/A

Sernova has a beta of -0.276836, meaning that its share price is 128% less volatile than the broader market. Comparatively, Helix BioPharma has a beta of 0.403644, meaning that its share price is 60% less volatile than the broader market.

In the previous week, Helix BioPharma had 1 more articles in the media than Sernova. MarketBeat recorded 1 mentions for Helix BioPharma and 0 mentions for Sernova. Helix BioPharma's average media sentiment score of 0.67 beat Sernova's score of 0.00 indicating that Helix BioPharma is being referred to more favorably in the news media.

Company Overall Sentiment
Sernova Neutral
Helix BioPharma Positive

Summary

Sernova beats Helix BioPharma on 7 of the 10 factors compared between the two stocks.

How does Sernova compare to Scythian Biosciences?

Sernova (TSE:SVA) and Scythian Biosciences (CVE:SCYB) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends and profitability.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SernovaN/AN/A-C$35.70M-C$0.04N/A
Scythian BiosciencesN/AN/AN/AN/AN/A

Sernova's return on equity of 51.72% beat Scythian Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
SernovaN/A 51.72% -119.26%
Scythian Biosciences N/A N/A N/A

0.0% of Sernova shares are owned by institutional investors. 12.1% of Sernova shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Sernova's average media sentiment score of 0.00 equaled Scythian Biosciences'average media sentiment score.

Company Overall Sentiment
Sernova Neutral
Scythian Biosciences Neutral

Summary

Sernova beats Scythian Biosciences on 3 of the 4 factors compared between the two stocks.

Get Sernova News Delivered to You Automatically

Sign up to receive the latest news and ratings for SVA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SVA vs. The Competition

MetricSernovaBiotechnology IndustryMedical SectorTSE Exchange
Market CapC$52.16MC$465.73MC$6.25BC$11.80B
Dividend Yield7.86%3.87%2.80%6.23%
P/E Ratio-3.753.7620.7937.14
Price / SalesN/A7,435.94531.2111.26
Price / Cash6.1513.1343.0982.29
Price / Book-1.9783.539.814.35
Net Income-C$35.70M-C$96.07MC$3.55BC$299.09M
7 Day PerformanceN/A0.52%-2.07%-2.22%
1 Month Performance-18.92%0.18%-3.90%-1.01%
1 Year Performance-25.00%71.17%29.39%53.16%

Sernova Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SVA
Sernova
N/AC$0.15
-3.2%
N/A-22.5%C$52.16MN/AN/A1,959
TH
Theratechnologies
0.0974 of 5 stars
C$4.47
-4.9%
N/A+22.8%C$205.53MC$84.38MN/A103
BCT
BriaCell Therapeutics
N/AC$10.60
-3.8%
N/A+0.0%C$168.68MN/AN/A5
IPA
ImmunoPrecise Antibodies
N/AC$6.50
+0.8%
N/A+0.0%C$162.08MC$19.47MN/A80
HBP
Helix BioPharma
N/AC$1.60
-2.4%
N/A+64.6%C$122.21MN/AN/A9

Related Companies and Tools


This page (TSE:SVA) was last updated on 5/19/2026 by MarketBeat.com Staff.
From Our Partners